Journal of Child and Adolescent Psychopharmacology, 1998; 37:12, 1271-1278.
An Open Trial of Buproprion in Adolescents with Substance Use Disorders and Conduct Disorder.
Riggs, P. D., Leon S. L., Mikulich, S. K., & Pottle, L. C.
Pilot data are presented from a 5-week, open-label buproprion trial in 13 nondepressed adolescent boys in a residential treatment program focusing on substance and behavioral treatments. All had diagnoses of attention deficit hyperactivity disorder (ADHD), conduct disorder (CD) and substance use disorder (SUD). Patient's doses were titrated to a maximum fixed daily dose of 300 mg of buproprion. Subjects were rated on several measures at baseline and at the fifth week of treatment. The results show that the subject's mean Conners Hyperactivity Index score declined 13%, mean Daydream Attention score declined 10% and mean Clinical Global Impressions Severity of Illness (CGI-S) declined 39%. These preliminary data suggest that buproprion may be a useful treatment for ADHD in adolescents with CD and SUD; they suggest the need for a controlled trial of buproprion in such youths.